Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Allogene Therapeutics (ALLO) EPS (Basic): 2018-2024

Historic EPS (Basic) for Allogene Therapeutics (ALLO) over the last 7 years, with Dec 2024 value amounting to -$1.32.

  • Allogene Therapeutics' EPS (Basic) rose 40.62% to -$0.19 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.98, marking a year-over-year increase of 37.18%. This contributed to the annual value of -$1.32 for FY2024, which is 36.84% up from last year.
  • According to the latest figures from FY2024, Allogene Therapeutics' EPS (Basic) is -$1.32, which was up 36.84% from -$2.09 recorded in FY2023.
  • Allogene Therapeutics' 5-year EPS (Basic) high stood at -$1.32 for FY2024, and its period low was -$2.63 during FY2020.
  • Its 3-year average for EPS (Basic) is -$1.93, with a median of -$2.09 in 2023.
  • As far as peak fluctuations go, Allogene Therapeutics' EPS (Basic) spiked by 49.05% in 2021, and later tumbled by 77.61% in 2022.
  • Over the past 5 years, Allogene Therapeutics' EPS (Basic) (Yearly) stood at -$2.63 in 2020, then surged by 49.05% to -$1.34 in 2021, then crashed by 77.61% to -$2.38 in 2022, then increased by 12.18% to -$2.09 in 2023, then soared by 36.84% to -$1.32 in 2024.